BiotechTube

MAS825 + Standard of Care (SoC)

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID-19 Pneumonia, Impaired Respiratory Function

Conditions

COVID-19 Pneumonia, Impaired Respiratory Function

Trial Timeline

Jun 11, 2020 → Apr 21, 2021

NCT ID
NCT04382651

About MAS825 + Standard of Care (SoC)

MAS825 + Standard of Care (SoC) is a phase 2 stage product being developed by Novartis for COVID-19 Pneumonia, Impaired Respiratory Function. The current trial status is completed. This product is registered under clinical trial identifier NCT04382651. Target conditions include COVID-19 Pneumonia, Impaired Respiratory Function.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04382651Phase 2Completed

Competing Products

20 competing products in COVID-19 Pneumonia, Impaired Respiratory Function

See all competitors
ProductCompanyStageHype Score
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
DesidustatZydus LifesciencesPhase 2
52
LY3819253 + PlaceboEli LillyPhase 1
33
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + BebtelovimabEli LillyPhase 2
52
BamlanivimabEli LillyPhase 2
52
LY3127804 + PlaceboEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 3
77
BamlanivimabEli LillyPre-clinical
23
LY3819253 + Placebo + RemdesivirEli LillyPhase 3
77
LY3819253 + LY3832479 + LY3853113 + PlaceboEli LillyPhase 2/3
65

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85